Introducing a Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs

• Demonstrating rationale to develop masked ADCs to overcome challenges with target-mediated toxicity
• Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles
• Looking ahead: What is the potential for masked ADC technology to deliver improved safety performance and therapeutic index?

Speakers:

Ruud Coumans

Project Leader

Byondis